

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Applicants request that the information on the attached Form PTO-1449 be considered by the Office during the pendency of the above-entitled application, pursuant to 37 C.F.R. 1.97. In accordance with 37 C.F.R. 1.97(h), the filing of the Information Disclosure Statement shall not constitute an admission that any information cited therein is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b) or that the references cited constitute prior art under 35 U.S.C. §§ 102 and/or 103. In the interest of full and complete disclosure to the Office, some or all of the art cited herein may not be considered by Applicant(s) or the Undersigned to be material under the standards of materiality defined in C.F.R. 1.56(b), and may merely be technical background which may be of interest to the Examiner.

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Since no Office Action has issued, Applicants believe that no fee is due in connection with the filing of this Information Disclosure Statement. However, if any fee is due, please charge any fees that may be necessary or credit any overpayment to Deposit Account No. 03-3975, Order No.

018813/0282105.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: August 19, 2002



Suzanne L. Biggs  
Registration No. 30,158

Address Correspondence to:  
11682 El Camino Real, Suite 200  
San Diego, CA 92130  
Direct Line: (858) 509-4095  
Fax Line: (858) 509-5010  
Attorney for Applicant

AUG 20 2002

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Date: August 19, 2002

Page **1** of **2**

Atty. Dkt. No.	C/M#	Client Ref.
	018813-0282105	10-110-001US
Applicant: Semple, et al.		
Appln. No.: 10/092,004		
Filing Date: March 5, 2002		
Examiner: To be Assigned		Group Art Unit: To be Assigned

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR	5,492,895	02/1996	Vlasuk, et al.	514	18	02/14/94
BR	5,534,498	07/1996	Brunck, et al.	514	19	01/29/93
CR	5,658,939	08/1997	Abelman, et al.	514	414	04/18/95
DR	5,681,844	10/1997	Abelman, et al.	514	423	04/28/94
ER	5,696,231	12/1994	Abelman, et al.	530	331	12/21/94
FR	5,703,208	12/1997	Semple, et al.	530	331	06/07/95
GR	5,714,499	02/1998	Semple, et al.	514	316	06/17/94
HR	5,731,413	03/1998	Webb, et al.	530	331	06/07/95
IR	5,739,112	04/1998	Brunck, et al.	514	19	06/05/95
JR	5,770,600	06/1998	Abelman, et al.	514	237.2	06/06/95
KR	5,775,927	07/1998	Wider	439	188	12/30/96
LR	5,883,077	03/1999	Brunck, et al.	514	19	12/15/93
MR	5,886,146	03/1999	Vlasuk, et al.	530	331	06/02/95
NR	5,955,976	09/1999	Heath	314	87	12/02/97
OR	5,646,195	07/1997	Mobley	521	121	03/07/95
PR	5,972,616	10/1999	O'Brien, et al.	435	6	02/20/98
QR	6,025,472	02/2000	Abelman, et al.	530	331	06/07/95
RR	6,034,215	03/2000	Semple, et al.	530	331	10/14/97

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
SR	WO 00/05245	02/2000	PCT	Brunck, et al.	C07K 5/00	X		
TR	WO 00/53232	09/2000	PCT	Dickson, et al.	A61K 49/00	X		
UR	WO 01/29056 A1	04/2001	PCT	O'Brien, et al.	C07H 21/02	X		
VR	WO 01/57194 A2	08/2001	PCT	Madison, et al.	C12N 9/00	X		
WR	WO 01/97794 A2	12/2001	PCT	Lin, et al.	A61K 31/00	X		
XR	WO 02/08392 A2	01/2002	PCT	Xiao, et al.	C12N 9/00	X		

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

YR /	Bock, P.E., et al., Isolation of human blood coagulation $\alpha$ -factor $X_a$ by soybean trypsin inhibitor -- sepharose chromatography and its active-site titration with fluorescein mono- <i>p</i> -guanidinobenzoate <sup>1</sup> , <i>Archives of Biochemistry and Biophysics</i> , 273(2): 375-388 (September 1989)		
ZR	Boring, C., Cancer Statistics, 1993, CA Cancer J. Clin., 43:7-26 (1993).		

6 2 002

AAR	Brooks, P.C., et al., Use of the 10-day-old chick embryo model for studying angiogenesis, <i>Methods in Molecular Biology</i> , 129:257-269 (1999)			
BBR	Enyedy, I.J., et al., Structure-based approach for the discover of Bis-benzamidines as novel inhibitors of matriptase, <i>J. Med. Chem.</i> , 44:1349-1355 (2001)			
CCR	Hunter, T., Cooperation between oncogenes, <i>Cell</i> , 64:249-270, (January 25, 1991)			
DDR	Land, H., et al., Cellular oncogenes and multistep carcinogenesis, <i>Science</i> 222:771-778 (November 18, 1983)			
EER	Lin, C., et al., Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity, <i>The Journal of Biological Chemistry</i> , 274(26):18231-18236 (June 25, 1999)			
FFR	Lin, C., et al., Purification and characterization of a complex containing matriptase and a kunitz-type serine protease inhibitor from human milk, <i>The Journal of Biological Chemistry</i> , 274(26):183237-18242 (June 25, 1999)			
GGR	McDonnell, S., et al., Stromelysin in tumor progression and metastasis, <i>Cancer and Metastasis Reviews</i> , 9:305-319 (1980)			
HHR	Mignatti, P., et al., Biology and biochemistry of proteinases in tumor invasion, <i>Physiological Reviews</i> , 73(1):161-195 (January 1993)			
IIR	Ossowski, L, In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface--bound urokinase, <i>The Journal of Cell Biology</i> , 107(No. 6 pt. 1):2437-2445 (December 1988)			
JJR	Ruly, H.E., Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture, <i>Nature</i> , 304:602-606 (August 18, 1993)			
KKR	Takeuchi, T., et al., Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates, <i>The Journal of Biological Chemistry</i> , 275(34):2633-26342 (August 25, 2000)			
LLR	Takeuchi, T., et al., Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue, <i>Proc. Natl. Acad. Sci. USA</i> , 96:11054-11061 (September 1999)			
MMR	Tamura, S.Y., et al., Novel benzo-fused lactam scaffolds as factor Xa inhibitors, <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 9:2573-2578 (1999)			
NNR	Seebach, D., et al., 107.stereoselektive alkylierung an C( $\alpha$ ) von serin, glycerinsäure, threomin und weinsäure über heterocyclische enolate mit exocyclischer doppelbindung <sup>1,2</sup> ), <i>Helvetica Chimica Acta</i> , 70:1194-1216 (1987)			

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.